An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2014
At a glance
- Drugs EMD 640744 (Primary) ; Montanide ISA-51
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Merck KGaA
- 03 Oct 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2010 Planned end date changed from 1 Oct 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.